Parkman Healthcare Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Parkman Healthcare Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-54,294	Closed	-$2.94M	–	100
2024 Q4	$2.94M	Sell	54,294 -48,519	-47%	-$2.48M	0.39%	62
2024 Q3	$5.18M	Buy	102,813 +1,589	+2%	+$74.5K	0.66%	52
2024 Q2	$4.45M	Buy	101,224 +153	+0.2%	+$6.48K	0.6%	59
2024 Q1	$5.08M	Buy	101,071 +19,062	+23%	+$1.03M	0.62%	52
2023 Q4	$4.95M	Buy	82,009 +28,716	+54%	+$1.48M	0.7%	46
2023 Q3	$3.04M	Sell	53,293 -26,707	-33%	-$1.47M	0.56%	52
2023 Q2	$4.08M	Buy	+80,000	New	+$2.15M	0.71%	45

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Parkman Healthcare Partners's MLTX Position: Q1 2025 in Review

Parkman Healthcare Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2025, closing a stake of 54,294 shares — an estimated $2.94M sold.

Parkman Healthcare Partners first reported a position in MLTX in Q2 2023 and held it in 7 quarters. The position peaked at $5.18M in Q3 2024. 136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

Parkman Healthcare Partners reported no remaining MoonLake Immunotherapeutics position as of Q1 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 54,294 MoonLake Immunotherapeutics shares in Q1 2025, an estimated $2.94M.
Parkman Healthcare Partners first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 7 quarters.
Parkman Healthcare Partners's MoonLake Immunotherapeutics position peaked at $5.18M in Q3 2024.
136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.